♥ HF Guideline NavigatorESC 2026

5 › 5.2

5.2 HF phenotypes based on LVEF

Pages 24–25 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 24 · PDF

required in the assessment of kidney function.164 UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥90 mL/min/ 1.73 m2. UACR has strong independent prognostic value for patients with HF.165,166 Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.167

Table 9 Causes for increase or decrease in natriuretic peptide levels Causes for increased natriuretic peptide levels Acute coronary syndrome Advanced agea Atrial fibrillation Cardiac contusion Critical illness Female sex Kidney dysfunction

LV hypertrophy Myocarditis

In patients with suspected HF, the following laboratory tests are recommended when

screening for comorbidities: full blood count,

kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids,

Pulmonary embolism Pulmonary hypertension

and iron status (TSAT and ferritin).168

Natriuretic peptide measurement is (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic

Severe endocrine dysfunction Severe infections (including pneumonia and sepsis)

A 12-lead ECG is recommended in patients with

Severe metabolic acidosis and diabetic ketoacidosis

Chest radiography (X-ray) is recommended in

patients with suspected HF.

in patients with suspected HF to confirm the

African ancestry ARNI /ACE-I/ARB

diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a See Figure 4. b ARNI may raise BNP levels.

5.1.2. Other laboratory tests Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy. Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are

ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Class of recommendation. b Level of evidence. c See Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.

5.2. Heart failure phenotypes based on left ventricular ejection fraction Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.

5.2.1. Heart failure with reduced ejection fraction The diagnosis of HFrEF requires the following criteria: (i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF <50%. Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the

Transthoracic echocardiogram is recommended

Causes for decreased natriuretic peptide levels

peptide levelc).146–148,151–153,169

recommended in patients with suspected HF

Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)

Page 25 · PDF

Table 10 Simplified echocardiographic criteria for supporting objective evidence of heart failure with preserved ejection fraction Criteria

≥115 g/m2 (male) OR Relative wall thickness >0.42 LA dilatation (volume indexed by BSA)

>34 mL/m2 (sinus rhythm) >40 mL/m2 (AF)

Increased likelihood of elevated LV filling pressure

Raised estimated systolic PA pressure

>35 mmHg OR TR velocity at rest >2.8 m/s

The probability for an HFpEF diagnosis increases with the number of parameters in the pathological range. AF, atrial fibrillation; BSA, body surface area; HFpEF, heart failure with preserved ejection fraction; LA, left atrial; LV, left ventricular; PA, pulmonary artery; TR, tricuspid regurgitation. a E/e′ ≥15 is more specific, but less sensitive, for the diagnosis of HFpEF.

only a minority of patients where the diagnosis is uncertain and where establishing the diagnosis or an alternative cause of signs or symptoms is likely to affect patient management. Therefore, current guidelines do not mandate invasive haemodynamic testing in every patient with suspected HFpEF to make the diagnosis.

5.3. Aetiology and subtypes of heart failure Assessment of aetiology is fundamental for the management of HF, as treatment should, if possible, address the underlying cause. Some treatments may be aetiology dependent, and some causes of HF are potentially reversible. Disease-modifying therapies are increasingly available, and early identification and treatment can improve survival. Targeted therapies for specific cardiomyopathies are under investigation, and precise aetiological assessment will become increasingly important in the future. Aetiology assessment also determines prognosis,177 is relevant to the patient, and imperative for care planning. Common causes of HF include ischaemic heart disease, hypertension, and valvular heart disease, although a multitude of other causes and contributing factors exist (Figures 5 and 6) and often more than one possible cause may be present. Determining the aetiology often involves a multiparametric evaluation beginning with obtaining a medical history from the patient, continuing through patient examination and clinical tests (Figure 7). Often non-invasive testing accompanied by medical history will be sufficient to determine aetiology. Characteristic findings indicating the underlying

(i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF ≥50% (requires that LVEF has not previously been <50%) (iii) Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures (Table 10), supported by raised natriuretic peptides (Figure 4). Testing for elevated levels of natriuretic peptides may in most patients support the diagnosis of HFpEF. However, diagnostic thresholds for HFpEF should be critically evaluated based on patient characteristics, especially in the presence of obesity and other factors that may cause reduced natriuretic peptide levels (Table 9).158 A pragmatic approach to the diagnosis of HFpEF is advised to facilitate access to diagnosis for the large population of elderly patients potentially affected. More complicated scoring systems171,172 have shown conflicting results in the community setting, but a meta-analysis indicates acceptable specificity and sensitivity for detection of HFpEF.173–175 If employed, diagnostic scoring systems should be interpreted with caution and used primarily to raise clinical suspicion of HFpEF rather than to establish a definitive diagnosis. In cases of diagnostic uncertainty, further investigations—such as cardiopulmonary exercise testing (CPET) [including measurement of peak oxygen consumption (VO2) to confirm reduced exercise capacity and elucidate the underlying cause of dyspnoea], exercise stress echocardiography, or invasive haemodynamic assessment— may be considered.176 The gold standard, confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing. An invasively measured pulmonary capillary wedge pressure of ≥15 mmHg (at rest), or ≥25 mmHg (with exercise), or an LV end-diastolic pressure ≥16 mmHg (at rest) is generally considered diagnostic. In recognition that invasive haemodynamic exercise testing is expensive and is not available in many centres worldwide, its main use should be limited to research settings or to patients with diagnostic uncertainty despite non-invasive testing. In most patients, the diagnosis of HFpEF can be made based on clinical history and echocardiographic signs (Table 10). Thus, invasive testing is indicated in

LV mass index ≥95 g/m2 (female)

5.2.2. Heart failure with preserved ejection fraction The diagnosis of HFpEF is more challenging and should start with the assessment of pre-test probability.170 Several clinical factors may contribute to or be associated with HFpEF, as illustrated in Figure 6. The more factors present the higher the likelihood of HFpEF. The following criteria must all be present for the diagnosis of HFpEF:

diagnostic pathway, especially if echocardiography is not readily available. However, many factors may cause false positive or false negative results, which should be considered when evaluating natriuretic peptide (Table 9). LVEF is a continuous measure and may differ between methods used as well as sex. For this reason, a precise value is only given as guidance. Aetiology assessment is important, as it may result in finding potential treatable and/or reversible causes. The major aetiologies of HFrEF are illustrated in Figure 5.